May 5, 2011 – Volcano Corp. announced a supply agreement with ev3, a Covidien company, under which Volcano will supply its intravascular ultrasound (IVUS) technology for use in ev3's plaque excision systems. Utilizing the digital IVUS transducer incorporated in Volcano's EagleEye catheter product line, this new product will be capable of running on Volcano's global installed base of 5,000 systems. "At Volcano, our imaging and physiology tools provide a level of precision that angiography alone simply cannot match," commented Scott Huennekens, president and CEO of Volcano. "In addition to our internally developed image-guided therapy products, such as the Vibe RX Imaging Balloon (commercially available in the EU only), we have looked to other medical device industry leaders to join us in differentiating therapeutic devices by adding integrated imaging capabilities. Covidien is an innovative company that recognizes the value of onboard visualization and is committed to bringing these new, more precise therapies to market to help improve patient outcomes. This agreement also exemplifies the value of our one system, many solutions strategy facilitated by our multi-modality platform." Plaque Excision Systems, also called atherectomy devices, are catheters that remove plaque that blocks arteries and interrupts blood flow. Instead of compressing plaque against the vessel wall – as is the case with balloon and stent therapy alone – plaque excision systems remove the obstruction from the vessel, thereby restoring blood flow, reducing damage to the vessel wall, and preserving future treatment options. IVUS integration offers advantages in immediate assessment of the plaque to better guide therapy. More than 270,000 atherectomy procedures have been performed with the SilverHawk and TurboHawk directional atherectomy catheters, which are designed to direct the therapy specifically to the diseased portion of the vessel while avoiding healthy portions of the vessel. The latest generation of TurboHawk plaque excision catheters are designed to remove all plaque morphologies from diseased arteries, including calcified lesions. "By partnering with Volcano, we continue to lead atherectomy therapy, enabling physicians to visualize the diseased portion of the artery for optimal plaque excision," said Stacy Enxing Seng, president, peripheral vascular, Covidien. "This is particularly important as we believe preparing and treating the vessel for drug delivery, whether via drug coated balloon or stent, will create a breakthrough in treating lower extremity peripheral arterial disease." For more information: www.volcanocorp.com
Technology | May 05, 2011
IVUS to be Integrated With Atherectomy Device
News | Atherectomy Devices | July 20, 2020
July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a private
News | Atherectomy Devices | February 13, 2020
February 13, 2020 — The U.S.
News | Atherectomy Devices | November 11, 2019
November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and effec
News | Atherectomy Devices | November 07, 2019
November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs.
Technology | Atherectomy Devices | September 13, 2019
Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Revolution...
News | Atherectomy Devices | July 18, 2018
Avinger Inc. announced in June that several physicians have successfully treated over 40 patients for peripheral artery...
Technology | Atherectomy Devices | May 24, 2018
Avinger Inc. announced that the company received 510(k) clearance from the U.S. Food & Drug Administration (FDA)...
Technology | Atherectomy Devices | January 16, 2018
Medtronic plc announced the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA)...
News | Atherectomy Devices | January 09, 2018
January 9, 2018 – Avinger Inc. announced that Arne Schwindt, M.D., a vascular surgeon at St.
Technology | Atherectomy Devices | November 20, 2017
November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S.